Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. engages in the manufacture and distribution of pharmaceutical products in the People's Republic of China. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2012-05-15. The firm produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The firm's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The firm operated in two business segment Wholesales segment and Retail segment. The firm's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The firm mainly conducts its businesses in the domestic market and overseas markets.